This phase 3 trial, conducted in the pre-rituximab era (1988–1995), established combined modality therapy as a standard of care in the pre-rituximab era. SWOG S8736 showed that three cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) with radiation therapy (RT) were non-inferior to eight cycles of CHOP alone. This defined a new standard treatment length and inclusion of radiation for limited-stage patients which has continued to serve as the foundation for subsequent dedicated limited-stage disease trials. SWOG S8736 also developed a risk stratification scoring system in limited-stage DLBCL that retains utility in the modern era. The International Prognostic Index (IPI) for DLBCL was adjusted to better stratify prognosis in limited-stage disease by removing the number of extranodal sites and dichotomizing stage as I versus II. This stage-modified IPI (smIPI) thus includes one point each for age > 60 years, stage II disease, elevated serum lactate dehydrogenase (LDH), and performance status of two or above. In the pre-rituximab era, those with no risk factors, and thus stage I disease, had the best outcomes with 5-year overall survival (OS) of 95% for those with one to two risk factors, 5-year OS dropped to 77%, and 50% for three or more risk factors. This smIPI model was more powerful than an age-adjusted risk stratification alone. In the rituximab era, outcomes in each IPI risk group have improved across both limited and advanced disease groups, and smIPI retains utility. The anti-CD20 monoclonal antibody, rituximab, improves survival in limited-stage disease just as it does for advanced-stage DLBCL. The MabThera International Trial (MInT) study found that non-bulky, limited-stage disease treated with R-CHOP had better 6-year event-free survival (EFS) at 84.3% and 6-year OS of 94.9% than CHOP alone. Notably, these survival benefits occurred without a significant increase in toxicity or rate of secondary hematologic malignancy in long-term follow-up. This study helped establish the superiority of chemoimmunotherapy in younger patients with a good prognosis, limited-stage DLBCL. The treatment of limited-stage DLBCL patients in the modern era has evolved to reconsider the role of RT, the optimal length of systemic therapy, and the emerging role of metabolic imaging via positron emission tomography (PET) in response-adapted management. Murawski, +16 authors V.This review will focus on therapies and studies focusing on limited-stage DLBCL (Table 1), the inherent challenges and future considerations for this disease, and our recommended approach to these patients as diagnostics and therapeutics continue to evolve in the modern era.ĭLBCL is increasingly understood to be a highly heterogeneous neoplasm with many variations in morphology, gene expression, and biological regulation. (RT) to bulky (B) and extralymphatic (E) disease in combination with 6xR-CHOP-14 or R-CHOP-21 in young good-prognosis DLBCL patients: Results of the 2x2 randomized UNFOLDER trial of the DSHNHL/GLA.},Īuthor=, Radiotherapy (RT) to bulky (B) and extralymphatic (E) disease in combination with 6xR-CHOP-14 or R-CHOP-21 in young good-prognosis DLBCL patients: Results of the 2x2 randomized UNFOLDER trial of the DSHNHL/GLA.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |